Anticoagulant use for the prevention of stroke in patients with atrial fibrillation: findings from a multi-payer analysis

BMC Health Services Research

Joseph Menzin³  Jeff Schein²  Samir Mody²  Gary Owens¹  Winnie Nelson²  Brian Macomson²  Aarti A Patel²  Duygu Bozkaya³  Kathleen Lang³ 

[1] Gary Owens Associates Inc, Ocean View, DE, USA;Janssen Scientific Affairs, LLC, Raritan, NJ, USA;Boston Health Economics, Inc, Waltham, MA, USA

关键词: Warfarin;    Atrial fibrillation;    Prevention;    Stroke;    Anticoagulant;   

Others  :  1126830
DOI  :  10.1186/1472-6963-14-329

 received in 2013-09-16, accepted in 2014-07-23,  发布年份 2014

【 摘 要 】

Background

Oral anticoagulation is recommended for stroke prevention in intermediate/high stroke risk atrial fibrillation (AF) patients. The objective of this study was to demonstrate the usefulness of analytic software tools for descriptive analyses of disease management in atrial AF; a secondary objective is to demonstrate patterns of potential anticoagulant undertreatment in AF.

Methods

Retrospective data analyses were performed using the Anticoagulant Quality Improvement Analyzer (AQuIA), a software tool designed to analyze health plan data. Two-year data from five databases were analyzed: IMS LifeLink (IMS), MarketScan Commercial (MarketScanCommercial), MarketScan Medicare Supplemental (MarketScanMedicare), Clinformatics™ DataMart, a product of OptumInsight Life Sciences (Optum), and a Medicaid Database (Medicaid). Included patients were ≥ 18 years old with a new or existing diagnosis of AF. The first observed AF diagnosis constituted the index date, with patient outcomes assessed over a one year period. Key study measures included stroke risk level, anticoagulant use, and frequency of International Normalized Ratio (INR) monitoring.

Results

High stroke risk (CHADS₂ ≥ 2 points) was estimated in 54% (IMS), 22% (MarketScanCommercial), 64% (MarketscanMedicare), 42% (Optum) and 62% (Medicaid) of the total eligible population. Overall, 35%, 29%, 38%, 39% and 16% of all AF patients received an anticoagulant medication in IMS, MarketScanCommercial, MarketScanMedicare, Optum and Medicaid, respectively. Among patients at high risk for stroke, 19% to 51% received any anticoagulant.

Conclusions

The AQuIA provided a consistent platform for analysis across multiple AF populations with varying baseline characteristics. Analyzer results show that many high-risk AF patients in selected commercial, Medicare-eligible, and Medicaid populations do not receive appropriate thromboprophylaxis, as recommended by treatment guidelines.

【 授权许可】

   
2014 Lang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
• [2]Naccarelli GV, Varker H, Lin J, Schulman KL: Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009, 104:1534-1539.
• [3]Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, et al.: Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220.
• [4]Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
• [5]Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF: Lifetime cost of stroke in the United States. Stroke 1996, 27:1459-1466.
• [6]Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
• [7]Boulanger L, Hauch O, Friedman M, Foster T, Dixon D, Wygant G, Menzin J: Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation. Ann Pharmacother 2006, 40:1024-1029.
• [8]Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, Ikeda Y, Uchiyama S, D'Agostino R, Ohman EM, Liau CS, Hirsch AT, Mas JL, Wilson PW, Corbalán R, Aichner F, Steg PG, REACH Registry Investigators: Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008, 156:855-863. 863
• [9]Cullen MW, Kim S, Piccini JP Sr, Ansell JE, Fonarow GC, Hylek EM, Singer DE, Mahaffey KW, Kowey PR, Thomas L, Go AS, Lopes RD, Chang P, Peterson ED, Gersh BJ, ORBIT-AF Investigators: Risks and benefits of anticoagulation in Atrial fibrillation: insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes 2013, 6(4):461-469.
• [10]Estes NA III, Halperin JL, Calkins H, Ezekowitz MD, Gitman P, Go AS, McNamara RL, Messer JV, Ritchie JL, Romeo SJ, Waldo AL, Wyse DG, Bonow RO, DeLong E, Goff DC Jr, Grady K, Green LA, Hiniker A, Linderbaum JA, Masoudi FA, Piña IL, Pressler S, Radford MJ, Rumsfeld JS, American College of Cardiology: ACC/AHA/physician consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) Developed in Collaboration with the Heart Rhythm Society. J Am Coll Cardiol 2008, 2008(51):865-884.
• [11]Piccini JP, Fraulo ES, Ansell JE, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Thomas LE, Kong MH, Lopes RD, Mills RM, Peterson ED: Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J 2011, 162:606-612.
• [12]Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith SC Jr, Priori SG, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, et al.: ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011, 2011(123):e269-e367.
• [13]Wess ML, Schauer DP, Johnston JA, Moomaw CJ, Brewer DE, Cook EF, Emons M: Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation. J Gen Intern Med 2008, 23:411-417.
• [14]Zimetbaum PJ, Thosani A, Yu HT, Xiong Y, Lin J, Kothawala P, et al.: Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med 2010, 123:446-453.
• [15]Gitlin M, Lee JA, Spiegel DM, Carson JL, Song X, Custer BS, Cao Z, Cappell KA, Varker HV, Wan S, Ashfaq A: Outpatient red blood cell transfusion payments among patients on chronic dialysis. BMC Nephrol 2012, 13:145.
• [16]Yiee JH, Saigal CS, Lai J, Copp HL, Churchill BM, Litwin MS: Timing of Orchiopexy in the United States: a Quality-of-Care Indicator. Urology 2012, 80:1121-1126.
• [17]Johnston JA, Cluxton RJ Jr, Heaton PC, Guo JJ, Moomaw CJ, Eckman MH: Predictors of warfarin use among Ohio medicaid patients with new-onset nonvalvular atrial fibrillation. Arch Intern Med 2003, 163:1705-1710.
• [18]Boccuzzi SJ, Martin J, Stephenson J, Kreilick C, Fernandes J, Beaulieu J, Hauch O, Kim J: Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed. Curr Med Res Opin 2009, 25:2853-2864.
• [19]Naccarelli GV, Johnston SS, Dalal M, Lin J, Patel PP: Rates and implications for hospitalization of patients >/=65 years of age with atrial fibrillation/flutter. Am J Cardiol 2012, 109:543-549.
• [20]Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 010, 31:2369-2429.
• [21]Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, Hinchey JA, Howard VJ, Jauch EC, Levine SR, Meschia JF, Moore WS, Nixon JV, Pearson TA, American Heart Association Stroke Council: Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42:517-584.
• [22]Abdel-Latif AK, Peng X, Messinger-Rapport BJ: Predictors of anticoagulation prescription in nursing home residents with atrial fibrillation. J Am Med Dir Assoc 2005, 6:128-131.
• [23]Pugh D, Pugh J, Mead GE: Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing 2011, 40:675-683.
• [24]Lane DA, Lip GY: Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. Stroke 2008, 39:7-9.
• [25]Lip GY, Agnelli G, Thach AA, Knight E, Rost D, Tangelder MJ: Oral anticoagulation in atrial fibrillation: a pan-European patient survey. Eur J Intern Med 2007, 18:202-208.